Results 11 to 20 of about 14,894 (236)

Mucormycosis: association with deferoxamine therapy [PDF]

The American Journal of Medicine, 1989
M ucormycosis is an uncommon acute and often fatal opportunistic fungal infection that usually occurs in patients with poorly controlled diabetes mellitus, acute leukemias, or other immunosuppressive conditions [1,2]. A new association, that of mucormycosis occurring in patients receiving deferoxamine therapy for iron or aluminum excess, has been ...
Daly, Annemarie L., Velazquez, Luis A., Bradley, Suzanne F., Kauffman, Carol A.   +3 more
  +9 more sources

Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction

Journal of Cardiovascular Magnetic Resonance, 2008
Background In thalassemia major (TM), severe cardiac siderosis can be treated by continuous parenteral deferoxamine, but poor compliance, complications and deaths occur.
Pibiri Martina, Agus Annalisa, Westwood Mark A, Smith Gillian C, Dessi Carlo, Galanello Renzo, Tanner Mark A, Nair Sunil V, Walker J Malcolm, Pennell Dudley J   +9 more
doaj   +1 more source

Deferoxamine Compensates for Decreases in B Cell Counts and Reduces Mortality in Enterovirus 71-Infected Mice

Marine Drugs, 2014
Enterovirus 71 is one of the major causative agents of hand, foot and mouth disease in children under six years of age. No vaccine or antiviral therapy is currently available.
Yajun Yang, Jing Ma, Jinghui Xiu, Lin Bai, Feifei Guan, Li Zhang, Jiangning Liu, Lianfeng Zhang   +7 more
doaj   +1 more source

Mechanisms underlying the promotion of functional recovery by deferoxamine after spinal cord injury in rats

Neural Regeneration Research, 2017
Deferoxamine, a clinically safe drug used for treating iron overload, also repairs spinal cord injury although the mechanism for this action remains unknown.
Jian Hao, Bo Li, Hui-quan Duan, Chen-xi Zhao, Yan Zhang, Chao Sun, Bin Pan, Chang Liu, Xiao-hong Kong, Xue Yao, Shi-qing Feng   +10 more
doaj   +1 more source

Protective Effects of Deferoxamine on Vestibulotoxicity in Gentamicin-Induced Bilateral Vestibulopathy Rat Model

Frontiers in Neurology, 2021
Introduction: Administration of aminoglycoside (AG) antibiotics is one of the most common causes of ototoxicity. This study aimed to determine the protective effects of deferoxamine, an iron-chelating agent, on vestibulotoxicity using an intratympanic ...
Hyo-Jung Kim, Jin-Ok Lee, Ji-Soo Kim, Ji-Soo Kim   +3 more
doaj   +1 more source

An overview of complications associated with deferoxamine therapy in thalassemia [PDF]

Journal of Nephropharmacology, 2021
Thalassemic syndromes are the most common genetic diseases in the world that are related to blood transfusion and iron overload in the body. In ß-thalassemia major multiple blood transfusions due to ineffective erythropoiesis lead to iron excess in the ...
Bijan Keikhaei, Neda Farmani-Anooshe, Mohammad Bahadoram, Mohammad-Reza Mahmoudian-Sani, Kosar Alikhani, Ammar Helalinasab   +5 more
doaj   +1 more source

Deferoxamine Alleviates Osteoarthritis by Inhibiting Chondrocyte Ferroptosis and Activating the Nrf2 Pathway

Frontiers in Pharmacology, 2022
Objective: Osteoarthritis (OA) is a common disease with a complex pathology including mechanical load, inflammation, and metabolic factors. Chondrocyte ferroptosis contributes to OA progression.
Zhou Guo, Jiamin Lin, Kai Sun, Jiayou Guo, Xudong Yao, Genchun Wang, Liangcai Hou, Jingting Xu, Jiachao Guo, Fengjing Guo   +9 more
doaj   +1 more source

Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major

Journal of Cardiovascular Magnetic Resonance, 2012
Background Combination therapy with deferoxamine and oral deferiprone is superior to deferoxamine alone in removing cardiac iron and improving left ventricular ejection fraction (LVEF).
Alpendurada Francisco, Smith Gill C, Carpenter John-Paul, Nair Sunil V, Tanner Mark A, Banya Winston, Dessi Carlo, Galanello Renzo, Walker John, Pennell Dudley J   +9 more
doaj   +1 more source

Injectable Thermosensitive Hydrogels for a Sustained Release of Iron Nanochelators

Advanced Science, 2022
Deferoxamine (DFO) is an FDA‐approved iron‐chelating agent which shows good therapeutic efficacy, however, its short blood half‐life presents challenges such as the need for repeated injections or continuous infusions.
Seung Hun Park, Richard S. Kim, Wesley R. Stiles, Minjoo Jo, Lingxue Zeng, Sunghoon Rho, Yoonji Baek, Jonghan Kim, Moon Suk Kim, Homan Kang, Hak Soo Choi   +10 more
doaj   +1 more source

The Role of Iron-Chelating Therapy in Improving Neurological Outcome in Patients with Intracerebral Hemorrhage: Evidence-Based Case Report

Medicina, 2023
Current primary intracerebral hemorrhage (ICH) treatments focus on limiting hematoma volume by lowering blood pressure, reversing anticoagulation, or hematoma evacuation.
Mochamad Iskandarsyah Agung Ramadhan, Shierly Novitawati Sitanaya, Ariadri Hafian Wulandaru Hakim, Yetty Ramli   +3 more
doaj   +1 more source